Showing 1951-1960 of 5063 results for "".
- Let the Sun Shine In? Research Reveals Why Sunbathers May Live Longer than Sun Avoidershttps://practicaldermatology.com/news/let-the-sun-shine-in-research-reveals-why-sunbathers-may-live-longer-than-sun-avoiders/2458634/Sunbathers tend to live longer than their shade-seeking counterparts despite their increased risk for skin cancer, but why? New research suggests that a decrease in heart disease and noncancer/non-heart disease deaths may explain the paradox.
- FDA Greenlights Taltz for Psoriasishttps://practicaldermatology.com/news/fda-greenlights-taltz-for-psoriasis/2458635/The U.S. Food and Drug Administration approved the IL-17A blocker Taltz (ixekizumab) for adults with moderate-to-severe plaque psoriasis. Taltz is marketed by Indianapolis, Indiana-based Eli Lilly and Company. Given via
- New System Depicts Skin Regeneration in Technicolorhttps://practicaldermatology.com/news/new-system-depicts-skin-regeneration-in-technicolor/2458638/Thanks to a genetically engineered line of technicolor zebrafish, researchers can now visualize skin regeneration at high resolution in real time. Many available methods rely on samples that are "snapshots" of cell growth and movement, but the new system, called Skinbow, c
- Dr. Henry Lim Begins Term as 2016 President-Elect of AADhttps://practicaldermatology.com/news/dr-henry-lim-begins-term-as-president-elect-of-aad/2458660/Congrats … Henry Lim, M.D., chair of the Department of Dermatology at Henry Ford Hospital is now the president-elect of the American Academy of Dermatology (AAD). In March 2017, he will become president and serve for one year. Dr. Lim is board certified in dermat
- Medical Professionals, Practical Dermatology® Board Members, Recognized for Outstanding Work in Psoriatic Disease Fieldhttps://practicaldermatology.com/news/medical-professionals-practical-dermatology-board-members-recognized-for-outstanding-work-in-psoriatic-disease-field/2458661/Nominated by patients and colleagues, recipients of the first annual National Psoriasis Foundation Medical Professionals Awards exemplify the outstanding work being done in the psoriatic disease
- Lumenis Supports the Launch of Restoring Heroes Foundation for Scar Patientshttps://practicaldermatology.com/news/lumenis-launches-restoring-heroes-foundation-for-scar-patients/2458658/Kim Phuc, the young girl who was immortalized in a photograph taken during the 1972 Napalm bombing, has come a long way since that fateful day. When the photo was taken, she was running away from her village, naked, after her clothing had been burnt off. South Vietnamese plane
- Cipher Launches Bionect Foamhttps://practicaldermatology.com/news/cipher-launches-bionect-foam/2458678/Cipher Pharmaceuticals’ prescription topical Bionect® is now available in the US in a lightweight foam preparation that holds its shape until application. The company says the for
- ChloraDerm Launches Pediatric Offeringhttps://practicaldermatology.com/news/chloraderm-launches-pediatric-offering/2458683/entrotech life sciences (ELS) announced the availability of FDA-Cleared ChloraDerm in a new 1.75"x 1.75" configuration, ideal for pediatric patient use. ChloraDerm is the only transparent film dressing containing the Chlorhexidine Advantage, a safe, colophony-and acid-free, edge-t
- Caladrius Biosciences Licenses Dermatology Cell Technology to AiVita Biomedicalhttps://practicaldermatology.com/news/caladrius-biosciences-licenses-dermatology-cell-technology-to-aivita-biomedical/2458698/Caladrius Biosciences, Inc., has licensed exclusive global rights to its cell-derived dermatological technology for topical skin applications to AiVita Biomedical, Inc. The company says this transaction supports its strategy to monetize non-core assets. AiVita, a biotechnology company, wa
- Biosimilar News: Sandoz Acquires Biosimilar Infliximab In EEA, FDA Panel Urges Approval of Biosimilar Infliximab in UShttps://practicaldermatology.com/news/biosimilar-new-sandoz-acquires-biosimilar-infliximab-in-eea-fda-panel-urges-approval-of-biosimilar-infliximab-in-us/2458705/Two days after a US Food and Drug Administration (FDA) advisory panel voted to recommend approval of the biosimilar form of Remicade (Infliximab), Novartis’ Sandoz unit has acquired rights to develop and commercialize a biosimilar to Remicade® (i